, Volume 63, Issue 1, pp 70–78 | Cite as

Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression

  • Jianping WangEmail author
  • Lan Hu
  • Yang Chen
  • Ting Fu
  • Tao Jiang
  • Aihua Jiang
  • Xiaoxing You
Original Article



Oxidative stress is an important mechanism for diabetic nephropathy. Studies showed that hemo oxygenase-1 (HO-1) expression in renal tissue of patients with diabetic nephropathy has upregulated, while the HO-1 can protect the body through anti-oxidative stress. The study aimed to preliminarily explore the molecular mechanism by observing the effect of Sitagliptin on HO-1 expression in renal tissue of rats with diabetic nephropathy.


The diabetic nephropathy rat model was established by STZ injection followed by intraperitoneal injection of sitagliptin with different concentrations. The mRNA expressions of HO-1 were detected by real-time PCR and Western blot and HO-1 enzyme activity change was detected by colorimetry. Human renal mesangial cell (HRMC) were cultured in vitro with high glucose concentration (30 μmol/L), phosphatidylinositol-3-kinase (PI3K) level and nuclear factor erythroid-2-related factor (Nrf2) content in cytoplasm and cell nucleus were observed before and after treatment with sitagliptin, as well as the action of in meditating HO-1 expression.


HO-1 mRNA, protein level, and HO-1 enzyme activity in renal tissue of rats with diabetic nephropathy were significantly increased after treatment with sitagliptin (P < 0.05). As comparison, the 24 h urinary microalbumin, creatinine, and boold urea nitrogen were all decreased after treatment of sitagliptin (P < 0.05). Similar results were observed after CoPP (an agonist of HO-1) treatment (P < 0.05). In contrast, ZnPP, an inhibitor of HO-1, significantly abrogated the inhibitory effect of sitagliptin (P < 0.05). Phosphorylation of PI3K and Nrf2 nuclear translocation under high-glucose concentration condition was induced by sitagliptin in HRMC. HO-1 expression was suppressed by pretreating HRMC with PI3K inhibitor or RNA interference.


Sitagliptin may induce HO-1 expression via activation of PI3K and Nrf2 in rats with diabetic nephropathy; HO-1 can improve the oxidative stress of diabetic nephropathy, eventually protect from diabetic nephropathy.


Sitagliptin Heme oxygenase-1 Diabetic nephropathy Phosphoinositide 3-kinase Nuclear factor erythroid-2 related factor (Nrf2) Phosphatidylinositol-3-kinase (PI3K) 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.


  1. 1.
    N.R. Robles, J. Villa, R.H. Gallego, Non-proteinuric diabetic nephropathy. J. Clin. Med. 4(9), 1761–1773 (2015)CrossRefGoogle Scholar
  2. 2.
    H. Wang, K. Cui, K. Xu, S. Xu, Association between plasma homocysteine andprogression of early nephropathy in type 2 diabetic patients. Int. J. Clin. Exp. Med. 8(7), 11174–11180 (2015)PubMedPubMedCentralGoogle Scholar
  3. 3.
    A. Tagawa, M. Yasuda, S. Kume, K. Yamahara, J. Nakazawa, M. Chin-Kanasaki, H. Araki, S.I. Araki, D. Koya, K. Asanuma, E.H. Kim, M. Haneda, N. Kajiwara, K. Hayashi, H. Ohashi, S. Ugi, H. Maegawa, T. Uzu, Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. Diabetes 65(3), 755–767 (2016)CrossRefGoogle Scholar
  4. 4.
    M.W. Mashitah, N. Azizah, N. Samsu, M.R. Indra, M. Bilal, M.V. Yunisa, AD. Arisanti, Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice. Diabetes Metab. Syndr. Obes. 8, 347–355 (2015).PubMedPubMedCentralGoogle Scholar
  5. 5.
    K. Schror, B.H. Rauch, Aspirin and lipid mediators in the cardiovascular system. Prostaglandins Other Lipid Mediat. 121(Pt A), 17–23 (2015)CrossRefGoogle Scholar
  6. 6.
    M. Kamiyama, M. Urushihara, T. Morikawa, Y. Konishi, M. Imanishi, A. Nishiyama, H. Kobori, Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy. Int. J. Mol. Sci. 14(11), 23045–23062 (2013)CrossRefGoogle Scholar
  7. 7.
    A. Zarjou, A. Agarwal, Heme oxygenase-1 as a target for TGF-beta in kidney disease. Semin. Nephrol. 32(3), 277–286 (2012)CrossRefGoogle Scholar
  8. 8.
    E.O. Ptilovanciv, G.S. Fernandes, L.C. Teixeira, L.A. Reis, E.A. Pessoa, M.B. Convento, M.J. Simoes, G.A. Albertoni, N. Schor, F.T. Borges, Heme oxygenase 1 improves glucoses metabolism and kidney histological alterations in diabetic rats. Diabetol. Metab. Syndr. 5(1), 3–10 (2013)CrossRefGoogle Scholar
  9. 9.
    J. Skov, Effects of GLP-1 in the kidney. Rev. Endocr. Metab. Disord. 15(3), 197–207 (2014)CrossRefGoogle Scholar
  10. 10.
    H. Mori, Y. Okada, T. Arao, Y. Tanaka, Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J. Diabetes Investig. 5(3), 313–319 (2014)CrossRefGoogle Scholar
  11. 11.
    Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun. 391(3), 1405–1408 (2010)CrossRefGoogle Scholar
  12. 12.
    Chen Yang, Wang Jianping, Jiang Aihua, Fu Ting, Deng Shanshan, The expression changes of the of 8-hydroxyl guanosine and superoxide dismutase in the kidney of diabetic rats and its effect of sitagliptin. Chin. J. Diabetes 23(1), 75–78 (2015)Google Scholar
  13. 13.
    A. Paine, B. Eiz-Vesper, R. Blasczyk, S. Immenschuh, Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem. Pharmacol. 80(12), 1895–1903 (2010)CrossRefGoogle Scholar
  14. 14.
    G. Czibik, G. Derumeaux, D. Sawaki, G. Valen, R. Motterlini, Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology. Basic Res. Cardiol. 109(6), 450 (2014)CrossRefGoogle Scholar
  15. 15.
    S.S. Kim, J. Lim, Y. Bang, J. Gal, S.U. Lee, Y.C. Cho, G. Yoon, B.Y. Kang, S.H. Cheon, H.J. Choi, Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J. Nutr. Biochem. 23(10), 1314–1323 (2012)CrossRefGoogle Scholar
  16. 16.
    H. Zhao, M. Ozen, R.J. Wong, D.K. Stevenson, Heme oxygenase-1 in pregnancy and cancer: similarities in cellular invasion, cytoprotection, angiogenesis, and immunomodulation. Front. Pharmacol. 5, 295 (2014)CrossRefGoogle Scholar
  17. 17.
    J. Fang, T. Seki, H. Maeda, Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61(4), 290–302 (2009)CrossRefGoogle Scholar
  18. 18.
    R.N. Frank, R.H. Amin, J.E. Puklin, Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Am. J. Ophthalmol. 127(6), 694–709 (1999)CrossRefGoogle Scholar
  19. 19.
    C. Dong, H. Zheng, S. Huang, N. You, J. Xu, X. Ye, Q. Zhu, Y. Feng, Q. You, H. Miao, D. Ding, Y. Lu, Heme oxygenase-1 enhances autophagy in podocytes as a protective mechanism against high glucose-induced apoptosis. Exp. Cell Res. 337(2), 146–159 (2015)CrossRefGoogle Scholar
  20. 20.
    S. Koyasu, The role of PI3K in immune cells. Nat. Immunol. 4(4), 313–319 (2003)CrossRefGoogle Scholar
  21. 21.
    G.E. Mann, J. Niehueser-Saran, A. Watson, L. Gao, T. Ishii, P. de Winter, R.C. Siow, Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng Li Xue Bao 59(2), 117–127 (2007)PubMedGoogle Scholar
  22. 22.
    A.S. Jimenez-Osorio, S. Gonzalez-Reyes, J. Pedraza-Chaverri, Natural Nrf2 activators in diabetes. Clin. Chim. Acta 448, 182–192 (2015)CrossRefGoogle Scholar
  23. 23.
    Y.S. Oh, H.S. Jun, Effects of Glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int. J. Mol. Sci. 19(1), 26 (2018)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jianping Wang
    • 1
    Email author
  • Lan Hu
    • 1
    • 2
  • Yang Chen
    • 1
  • Ting Fu
    • 1
  • Tao Jiang
    • 1
  • Aihua Jiang
    • 1
  • Xiaoxing You
    • 3
  1. 1.Department of EndocrinologyThe Second Affiliated Hospital of University of South ChinaHengyangChina
  2. 2.Department of EndocrinologyThe First people’s Hospital of Xiangtan CityXiangtanChina
  3. 3.University of South ChinaHengyangChina

Personalised recommendations